Royalty Pharma PLC · Q3 2022 earnings

Briefing

Royalty Pharma's financial results for Q3 2022 were reported, demonstrating growth in operating cash flow and adjusted cash receipts.

Royalty Pharma reported a 15% increase in net cash provided by operating activities, reaching $539 million, and a 2% increase in Adjusted Cash Receipts, totaling $597 million. The company announced transactions of up to $3.0 billion year-to-date, including $1.7 billion in upfront payments. Royalty Pharma increased its full-year 2022 guidance for Adjusted Cash Receipts to $2,750 to $2,800 million.

• Net cash provided by operating activities (GAAP) increased 15% to $539 million.
• Adjusted Cash Receipts increased 2% to $597 million, driven by strong portfolio performance and the acquisition of royalties on Trelegy.
• Adjusted EBITDA grew 3% to $548 million.
• Adjusted Cash Flow increased 26% to $441 million.

Headline financials

Revenue & EPS history

Royalty Pharma anticipates full-year 2022 Adjusted Cash Receipts to be between $2,750 million and $2,800 million. The guidance reflects an estimated foreign exchange impact of approximately -3% to -4% for full-year 2022 year/year Adjusted Cash Receipts growth, assuming current exchange rates prevail for the balance of 2022.